RXST — RxSight Cashflow Statement
0.000.00%
- $607.27m
- $370.18m
- $139.93m
- 74
- 30
- 11
- 32
Annual cashflow statement for RxSight, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 27.6 | -48.7 | -66.8 | -48.6 | -27.5 |
Depreciation | |||||
Non-Cash Items | -58.9 | 2.67 | 11.3 | 11.8 | 16.1 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -7.85 | -2.68 | -7.41 | -9.07 | -9.21 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -35.2 | -44.7 | -58.9 | -41.6 | -16.9 |
Capital Expenditures | -2.54 | -1.94 | -2.39 | -4.81 | -5.44 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 18.1 | -80 | 42.3 | -17.3 | -93.9 |
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 15.6 | -81.9 | 40 | -22.1 | -99.3 |
Financing Cash Flow Items | -0.687 | -0.132 | -1.38 | -4.28 | -5.54 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 25.2 | 137 | 6.33 | 61.5 | 123 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 5.63 | 10.7 | -12.6 | -2.19 | 7.05 |